

Human CD48/SLAMF2 Biotinylated Antibody

Antigen Affinity-purified Polyclonal Goat IgG Catalog Number: BAF3644

DESCRIPTION	
Species Reactivity	Human
Specificity	Detects human CD48/SLAMF2 in Western blots. In Western blots, less than 5% cross-reactivity with recombinant mouse CD48 and recombinant human OX40 is observed.
Source	Polyclonal Goat IgG
Purification	Antigen Affinity-purified
Immunogen	Mouse myeloma cell line NS0-derived recombinant human CD48/SLAMF2 Gln27-Ser220 Accession # P09326.2
Formulation	Lyophilized from a 0.2 µm filtered solution in PBS with BSA as a carrier protein. See Certificate of Analysis for details.
APPLICATIONS Please Note: Optimal diluti	ons should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.
,	Recommended Sample Concentration
Western Blot	0.1 μg/mL Recombinant Human CD48/SLAMF2 (Catalog # 3644-CD)
PREPARATION AND	STORAGE
Reconstitution	Reconstitute at 0.2 mg/mL in sterile PBS.
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
	 12 months from date of receipt -20 to -70 °C as supplied

BACKGROUND

CD48, also known as BLAST-1, BCM-1, and SLAMF2, is a 65 kDa GPI-linked protein in the CD2 family of immunoglobulin superfamily molecules (1-3). The human CD48 cDNA encodes a 243 amino acid (aa) precursor that includes a 26 aa signal sequence, a 194 aa mature protein that contains one Ig-like V-type domain and one Ig-like C2-type domain, and a 23 aa C-terminal propeptide (4). A soluble form of CD48 has been detected in the serum of lymphoid leukemia and arthritis patients (5). Human CD48 shares approximately 50% aa sequence identity with mouse and rat CD48. It shares 20%-26% aa sequence identity with comparable regions of human CD2 family members 2B4, CD2, BLAME, CD2F-10, CD84, CD229, CRACC, NTB-A, and SLAM. CD48 is expressed on most lineage-committed hematopoietic cells but not on hematopoietic stem cells or multipotent hematopoietic progenitors (4,6). Among dendritic cells (DC), CD48 is selectively expressed on circulating myeloid DC and resident bone marrow and thymus DC (7). CD2, 2B4, and heparan sulfate function as CD48 ligands (8-10). CD48 is competent to transduce signals and can also trigger signaling through CD2 or 2B4 (8,11). CD48-CD2 interactions promote T cell activation and class switching to IgG_{2a} in B cells (8,12). High affinity CD48-2B4 interactions can either promote or inhibit NK cell and cytotoxic T cell (CTL) activation (7,11,13,14). In mouse, CD48-2B4 ligation does not directly trigger CTL activity but enhances signaling from the T cell receptor (13). CD48-2B4 mediated inhibition of NK cell activity is distinct from MHC I-restricted mechanisms (15). CD48 expressed on NK cells is coactivating, whereas CD48 expressed on other cell types inhibits NK cell activation (14). Both CD48 expressing and nonexpressing cells can be targets of NK cell or CTL-mediated lysis (13,16).

1 month, 2 to 8 °C under sterile conditions after reconstitution. 6 months, -20 to -70 °C under sterile conditions after reconstitution

References:

- 1. Assarsson, E. et al. (2005) J. Immunol. 175:2045.
- 2. Bhat, R. et al. (2006) J. Leukocyte Biol. 79:417.
- 3. Loertscher, R. and P. Lavery (2002) Transpl. Immunol. 9:93.
- 4. Wong, Y.W. *et al.* (1990) J. Exp. Med. **171**:2115.
- 5. Smith, G.M. et al. (1997) J. Clin. Immunol. 17:502.
- 6. Keil, M.J. et al. (2005) Cell 121:1109.
- 7. Morandi, B. et al. (2005) J. Immunol. 175:3690.
- 8. Kato, K. et al. (1992) J. Exp. Med. 176:1241.
- 9. Latchman, Y. et al. (1998) J. Immunol. 161:5809.
- 10. Ianelli, C.J. *et al.* (1998) J. Biol. Chem. **273**:23367.
- 11. Messmer, B. et al. (2006) J. Immunol. 176:4646.
- 12. Gao, N. et al. (2005) J. Immunol. 174:4113.
- 13. Lee, K-M. et al. (2003) J. Immunol. 170:4881.
- 14. Lee, K-M. et al. (2006) Blood **107**:3181.
- 15. McNerney, M.E. et al. (2005) Blood 106:1337.
- 16. Lee, K-M. et al. (2004) J. Exp. Med. 199:1245.

